SAN FRANCISCO – Now that the first generation of drug-eluting stents has more or less found its way into medical history and the bioresorbables are still grinding out clinical trial data, the time is apparently ripe for a firm that has staked its future on a dual-elution design to clamp down on restenosis and thrombosis.